



PetMed Express, Inc. (PETS)

Updated November 19th, 2023 by Felix Martinez

Key Metrics

Current Price:	\$8	5 Year CAGR Estimate:	-13.0%	Market Cap:	\$155.6 M
Fair Value Price:	\$3	5 Year Growth Estimate:	20.0%	Ex-Dividend Date:	N/A
% Fair Value:	700%	5 Year Valuation Multiple Estimate:	-53.8%	Dividend Payment Date:	N/A
Dividend Yield:	0.0%	5 Year Price Target	\$3	Years Of Dividend Growth:	0
Dividend Risk Score:	F	Retirement Suitability Score:	D	Rating:	Sell

Overview & Current Events

PetMed Express was founded in 1996 by Marc Puleo. PETS originally grew through word of mouth, television commercials, and catalogs. Now, the company is America's most trusted pet pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs, cats, and horses at competitive prices direct to the consumer through its toll-free number and on the Internet through its website. The company headquarters is in Delray Beach, Florida. PetMed Express, Inc. trades hands in the Nasdaq using the ticker symbol PETS. PETS has been growing its dividend for over thirteen years and made \$259.6 million in sales for Fiscal Year (FY) 2023. Currently, PetMed Express has a market cap of \$155.6 million.

On October 30th, 2023, PetMed Express reported second-quarter results for the Fiscal Year 2024. The company fiscal year ends on the last day of March every year. In this period, the company experienced a noteworthy increase in net sales, reaching \$71.0 million, a 9% rise compared to the same quarter the previous year. This growth was attributed in part to the inclusion of results from the recently acquired PCRx.

One notable highlight was a 25% year-over-year increase in new customers during the same quarter, marking the fourth consecutive quarter of new customer growth. This figure incorporates customers gained through the acquisition of PetCareRx.

However, the financial report also revealed a net loss of \$70 thousand for the quarter ending September 30, 2023, equivalent to \$(0.00) per diluted share. This contrasts with the prior year's net income of \$2.6 million, or \$0.13 diluted earnings per share, for the quarter ending September 30, 2022.

The Adjusted EBITDA1 for the current year quarter was \$3.2 million, reflecting a 55% decrease from the \$7.1 million reported for the quarter ending September 30, 2022. This decline was attributed to additional General and Administrative (G&A) expenses, partially resulting from the recent acquisition, as well as strategic investments in PetMeds' legacy third-party expenses and net advertising expenses. However, this was partially offset by increased gross profit and other income. The company also announced that the dividends will be suspended to invest in projects and initiatives that can give better returns.

Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
EPS	\$0.90	\$0.92	\$1.02	\$1.17	\$1.82	\$1.84	\$1.29	\$1.52	\$1.04	\$0.01	\$0.01	\$0.01
DPS	\$0.66	\$0.68	\$0.72	\$0.76	\$0.85	\$1.06	\$1.08	\$1.14	\$1.20	\$1.20	\$.68	\$0.00
Shares¹	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.3	20.3	20.4

The most significant growth prospects for PedMed Express are through online advertising and continuing to grow to reorder sales as it did for FY2021. We expect a20% earnings growth for the next five years as eCommerce grows and more people have pets as family members. The 20% earnings growth is because it will be coming from \$0.01 per share earnings in 2023. The company, throughout the years, has not repurchased shares to help earnings growth. Revenue has

¹ Share count is in millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



PetMed Express, Inc. (PETS)

Updated November 19th, 2023 by Felix Martinez

been steadily growing from 2.9% ten-year CAGR. Net Margin is also up year over year to 9.9%. Over the last five years, PETS has been increasing its dividend at a 2.5% compound annual growth rate. However, they announced that the dividend will be suspended.

Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/E	15.7	17.2	20.4	27.5	12.7	16.5	21.9	23.14	25.7	---	79.8	16.0
Avg. Yld.	4.9%	4.1%	4.0%	3.8%	2.0%	4.7%	3.8%	3.4%	4.7%	7.4%	9.4%	---

PetMed has a PE ratio very high based on FY2024 expected earnings of \$0.01 per share. This is much higher than the company's ten-year PE average of 20.6x earnings. As a base case, we think a fair multiple of 16x earnings would be fair value for the current expected future earnings growth. Thus, the company looks to be overvalued at the current price.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	73.3%	73.9%	70.6%	65.0%	46.7%	57.6%	83.7%	75.0%	115%	---	---	---


PetMed does not have a substantial competitive advantage today. We think the company has a narrow moat currently. The company is an online business that is easy for competitors to get into. However, The company does have a slight advantage as it has been in business since 1996, and PetMed Express is a very well-known company among pet lovers. During the Great Recession of 2008-2009, the company continued to grow its earnings from \$0.82 per share in FY2008 to \$0.98 per share in FY2009. Coming out of the Great Recession, PetMed made \$1.14 per share in FY2010. Thus, the company looks resilient during the Great Recession and the COVID-19 pandemic.

The company has an outstanding balance sheet. The only debt PetMed has is \$45.6 million with \$160 million in assets.

Final Thoughts & Recommendation

PetMed is a solid company with many things to like. The outstanding balance sheet is top-rated. Also, the company has had Free Cash Flow growth year in and year out. The only risk we see is that it has a narrow moat and is accessible for competitors to get into the pet medication business. We expect the stock to return negative (13.0)% annually for the next five years. Thus, we rate PetMed as a sell at the current price.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



PetMed Express, Inc. (PETS)

Updated November 19th, 2023 by Felix Martinez

Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Revenue	233	229	235	249	274	283	284	309	273	257
Gross Profit	78	76	76	79	98	95	81	90	78	71
Gross Margin	33.3%	33.2%	32.5%	31.8%	35.7%	33.6%	28.6%	29.1%	28.6%	27.6%
SG&A Exp.	49	46	43	40	44	47	48	50	50	69
D&A Exp.	1	1	1	1	2	2	2	2	3	4
Operating Profit	28	29	32	37	52	46	31	38	26	-1
Operating Margin	12.1%	12.8%	13.8%	15.0%	19.0%	16.3%	10.9%	12.2%	9.4%	
Net Profit	18	17	21	24	37	38	26	31	21	0.2
Net Margin	7.7%	7.6%	8.8%	9.6%	13.6%	13.3%	9.1%	9.9%	7.7%	0.0%
Free Cash Flow	13	31	1	37	37	45	37	38	17	23
Income Tax	10	10	12	14	17	11	8	9	6	1

Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Assets	78	83	90	113	135	154	155	187	176	164
Cash & Equivalents	18	36	38	59	78	101	104	119	111	104
Accounts Receivable	2	2	2	2	2	3	4	3	2	2
Inventories	36	25	26	20	23	21	18	34	32	19
Goodwill & Int. Ass.	1	1	1	1	1	1	1	1	1	6
Total Liabilities	8	7	7	19	19	20	25	46	34	40
Accounts Payable	6	5	5	15	15	16	20	40	28	25
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Shareholder's Equity	70.2	75.4	83.2	93.4	115.7	134.7	130.0	141.3	142.2	123.8
D/E Ratio	0	0	0	0	0	0	0	0	0	0

Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Assets	23.7%	21.7%	23.8%	23.5%	30.1%	26.1%	16.7%	17.9%	11.6%	0.14%
Return on Equity	26.8%	24.0%	25.9%	27.0%	35.7%	30.1%	19.5%	22.6%	14.9%	0.18%
ROIC	26.8%	24.0%	25.9%	27.0%	35.7%	30.1%	19.5%	22.6%	14.9%	0.18%
Shares Out.	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.4	20.3
Revenue/Share	11.64	11.39	11.59	12.23	13.40	13.83	14.17	15.37	13.43	12.63
FCF/Share	0.67	1.55	0.05	1.80	1.79	2.17	1.82	1.87	0.82	1.11

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.